Education
About Us
Working with TipRanks
Follow Us
Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)5.63M
Market Cap
AU$227.35M
Enterprise ValueAU$170.70M
Total Cash (Recent Filing)AU$3.00M
Total Debt (Recent Filing)AU$11.85M
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding797,709,500
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.96
Price to Sales (P/S)0.97
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$18.05M
Bulls Say, Bears Say
Bulls Say
Material U.S. Distribution AgreementA guaranteed 6-year USD 317M minimum distribution deal materially de-risks commercial rollout and provides multi-year revenue visibility. Structurally this creates a secured revenue backlog, helps planning for manufacturing and sales investment, and aligns a commercial partner to scale U.S. adoption.
Regulatory Pathway Progressing (CLIA Waiver Submitted)A CLIA waiver would permanently expand the addressable market by enabling point-of-care, in-office use, shortening adoption cycles and increasing repeat volumes. Achieving waiver changes the product's distribution channel dynamics and structurally increases physician-office demand and recurring consumable sales.
High Product Margins And Improved Operating Cash FlowSustained high product margins (≈60%+) combined with operating cash flow turning slightly positive and nondilutive BARDA receipts show improving unit economics and cash resilience. Structurally strong gross margins support profitable scale once volume ramps and reduce reliance on dilutive financing.
Bears Say
Declining Revenue And Continued UnprofitabilityA sustained revenue decline and persistent negative margins undermine the company's ability to self-fund growth and invest in commercialization. Structurally this increases dependency on external funding, raises execution risk for multi-year programs, and lengthens the path to durable profitability.
High Leverage And Weak Balance SheetSignificant leverage and negative ROE constrain financial flexibility for capex and scaling initiatives. Structurally, elevated debt amplifies refinancing and interest risks, reducing room to absorb commercial setbacks and increasing the need for careful liquidity management as the business scales.
Commercial Ramp Contingent On CLIA Waiver; Capacity NeedsThe business model's material upside is binary on regulatory approval and dependent on timely scale-up. If a waiver is delayed or capacity investment lags, guaranteed PHASE volumes could be jeopardized or require expensive outsourcing, creating structural execution and capital intensity risks for sustained growth.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.02 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$227.35M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Aug 25, 2026 which is in 167 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 797,709,500 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.843%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
551.51%
12-Months-Change
Fundamentals
Return on Equity
-111.23%
Trailing 12-Months
Asset Growth
-20.97%
Trailing 12-Months
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―